Her2 vaccine composition
AssigneeAston Sci. Co., Ltd.
InventorMary L. DISIS
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method for predicting reactivity of a HER2-ICD DNA vaccine composition, that is, the acquisition of immunogenicity and the therapeutic efficacy thereof, by measuring immunogenicity against a HER2-ICD antigen before vaccination. Additionally, by using the method for predicting reactivity, according to the present disclosure, a DNA vaccination target may be selected.
Claims9
A method for predicting the reactivity of a HER2-ICD DNA vaccine, comprising examining immunogenicity against a HER2-ICD antigen in peripheral blood mononuclear cells (PBMCs) of a patient to be vaccinated with a HER2-ICD (intracellular domain) DNA vaccine, before vaccination.
(canceled)
Dependencies are inferred from the claim text.